Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Elucidating Novel BTKi Strategies in CLL/SLL and MCL: A Virtual Exploration to Bring Therapeutic Rationales and Evidence into Perspective

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Activity Overview

This online, on-demand, virtual symposium brings together renowned experts in hematologic malignances to discuss the state of the art in therapy for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), and will also illustrate innovations incorporated into next-generation Bruton's tyrosine kinase inhibitors. Case-based panel discussions will help illustrate how current and emerging approaches can be applied to address unmet medical needs in patients with CLL/SLL and MCL.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Lilly.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Instructions for This Activity and Receiving Credit

Complete the activity (including pre- and post-activity assessments).
Answer the evaluation questions.
Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in the treatment of patients with lymphoid malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with lymphoid malignancies are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Describe the mechanisms of action of BTK inhibitors including distinctions between first- and later-generation agents.
Evaluate safety and efficacy data from clinical trials of BTK inhibitors in CLL/SLL and MCL.
Apply data from trials of BTK inhibitors to clinical scenarios in CLL/SLL and MCL.
Assess strategies to monitor and mitigate adverse events associated with BTK inhibitors used in the treatment of hematologic malignancies.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

Chair

William G. Wierda, MD, PhD
D.B. Lane Cancer Research Distinguished Professor
Section Chief, Chronic Lymphocytic Leukemia
Center Medical Director
Department of Leukemia, Division of Cancer Medicine
Executive Medical Director, Inpatient Medical Services
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: GlaxoSmithKline/Novartis, AbbVie, Genentech, Pharmacyclics LLC, AstraZeneca/Acerta Pharma, Gilead Sciences, Juno Therapeutics, Kite Pharma, Sunesis, Miragen, Oncternal Therapeutics, Cyclacel, Loxo Oncology, Inc., Janssen, Xencor; Consultant: Sanofi.

Faculty

Peter Martin, MD
Associate Professor
Director, Lymphoma Program
NewYork-Presbyterian Weill Cornell Medical Center
New York, NY

Disclosures: Grant/Research Support: Karyopharm; Consultant: ADC Therapeutics, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Gilead Sciences, Incyte, Janssen, MorphoSys, Regeneron.

Stephen J. Schuster, MD
Professor
Director, Lymphoma Program
Lymphoma Translational Research
University of Pennsylvania
Philadelphia, PA

Disclosures: Grant/Research Support: AbbVie, Acerta Pharma, Celgene, Genentech/Roche, Juno Therapeutics, Merck, Novartis; Consultant: Acerta Pharma, Allogene, AstraZeneca, BeiGene, Celgene, Genentech/Roche, Incyte, Juno Therapeutics, Loxo Oncology, Nordic Nanovector, Novartis.

Michael Wang, MD
Professor
Director, Mantle Cell Lymphoma Program of Excellence
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Acerta Pharma, AstraZeneca, BeiGene, BioInvent, Celgene, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Lilly, Loxo Oncology, Molecular Templates, Oncternal Therapeutics, Pharmacyclics, VelosBio; Consultant: AstraZeneca, Bayer, BeiGene, CStone, Zhejiang DTRM Biopharma Co. Ltd., Epizyme, Genentech, InnoCare, Janssen, Juno Therapeutics, Kite Pharma, Loxo Oncology, Miltenyi Biomedicine, Oncternal Therapeutics, Pharmacyclics, VelosBio; Speaker’s Bureau: Acerta Pharma, Anticancer Association, AstraZeneca, BeiGene, Chinese American Hematologist and Oncologist Network (CAHON), Chinese Medical Association, Clinical Care Options, DAVA Oncology, Epizyme, Hebei Cancer Prevention and Treatment Federation, Imedex, Janssen, Kite Pharma, Miltenyi Biomedicine, Moffitt Cancer Center.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.